Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Argent Biopharma ( (AU:RGT) ).
Argent Biopharma Limited announced the cessation of certain securities, specifically the lapse of 306,000 performance rights and the expiry of 250 Class D performance rights as of April 30, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s performance and future prospects.
More about Argent Biopharma
Argent Biopharma Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is listed on the Australian Securities Exchange (ASX) under the issuer code RGT.
YTD Price Performance: -25.00%
Average Trading Volume: 1,165
Technical Sentiment Signal: Buy
Current Market Cap: $5.15M
See more data about RGT stock on TipRanks’ Stock Analysis page.